The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of INSYS Therapeutics, Inc. (NASDAQ: INSY) who purchased shares between February 23, 2016 and March 15, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS public statements were materially false and misleading at all relevant times.
Shareholders have until May 16, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.